

**Cancer Prevention and Control CIRB Meeting Agenda**

**May 27, 2021**

---

---

**I. Continuing Review**

**A171601**, A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer (Protocol Version Date 05/29/20)

---

---

**II. Continuing Review**

**A221805**, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Protocol Version Date 07/22/20)

---

---

**III. Continuing Review**

**S1600**, A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMmune) (Protocol Version Date 01/20/21)

---

---

**IV. Continuing Review**

**UWI2015-05-01**, Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect (Protocol Version Date 04/14/21)

---

---

**V. New Study - Initial Review**

**A211901**, Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions (Protocol Version Date 04/13/21)

---

---

**VI. New Study - Initial Review**

**A222004**, A Randomized Phase III Trial Of Olanzapine Versus Megestrol Acetate For Cancer-Associated Anorexia (Protocol Version Date 04/01/21)

---

---

**VII. Amendment**

**A221805**, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Protocol Version Date 04/02/21)

---

---

---

---

**VIII. Amendment**

**S1614, A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors (Protocol Version Date 04/21/21)**

---

---